Is imatinib a cost-effective treatment for newly diagnosed chronic myeloid leukemia patients?

Nature clinical practice. Oncology ·Vol. 2 ·No. 3 ·2005-03-00 ·Pages 126-7

Goldman J

Abstract

暂无摘要

MeSH Terms

Antineoplastic Agents/economics,therapeutic use Benzamides Clinical Trials as Topic Cost-Benefit Analysis Humans Imatinib Mesylate Interferon-alpha/economics,therapeutic use Leukemia, Myelogenous, Chronic, BCR-ABL Positive/drug therapy,economics Piperazines/economics,therapeutic use Pyrimidines/economics,therapeutic use Quality-Adjusted Life Years Retrospective Studies Survival Analysis

Chemicals

Antineoplastic Agents Benzamides Interferon-alpha Piperazines Pyrimidines Imatinib Mesylate

Authors & Affiliations

1 authors, click to expand affiliations / ORCID

Goldman John

Department of Hematology, Imperial College at Hammersmith Hospital, London, UK. [email protected]

Article Info

Journal

Nature clinical practice. Oncology

Abbr.

Nat Clin Pract Oncol

ISSN

1743-4254

DOI

10.1038/ncponc0110

[email protected]

Published

2005-03-00

Pages

126-7

Language

English

Region

England

NLM ID

101226509

Subset

External Links

PubMed source DOI: 10.1038/ncponc0110 View journal details

Analysis Services

Is imatinib a cost-effective treatment for newly diagnosed chronic myeloid leukemia patients?

Contact

WeChat Official Account